Universität zu Köln

Niessl, Julia ORCID: 0000-0001-8852-1924, Baxter, Amy E., Mendoza, Pilar, Jankovic, Mila, Cohen, Yehuda Z., Butler, Allison L., Lu, Ching-Lan, Dube, Mathieu ORCID: 0000-0002-5522-9019, Shimeliovich, Irina, Gruell, Henning, Klein, Florian, Caskey, Marina, Nussenzweig, Michel C. and Kaufmann, Daniel E. (2020). Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med., 26 (2). S. 222 - 244. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1546-170X

Full text not available from this repository.

Abstract

T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antibodies with prolonged suppression of blood viremia during antiretroviral treatment interruption. Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir(1,2). Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy(3). However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8(+) T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption(4). Increased CD4(+) T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Niessl, Julia UNSPECIFIED orcid.org/0000-0001-8852-1924 UNSPECIFIED Baxter, Amy E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mendoza, Pilar UNSPECIFIED UNSPECIFIED UNSPECIFIED Jankovic, Mila UNSPECIFIED UNSPECIFIED UNSPECIFIED Cohen, Yehuda Z. UNSPECIFIED UNSPECIFIED UNSPECIFIED Butler, Allison L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lu, Ching-Lan UNSPECIFIED UNSPECIFIED UNSPECIFIED Dube, Mathieu UNSPECIFIED orcid.org/0000-0002-5522-9019 UNSPECIFIED Shimeliovich, Irina UNSPECIFIED UNSPECIFIED UNSPECIFIED Gruell, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Klein, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Caskey, Marina UNSPECIFIED UNSPECIFIED UNSPECIFIED Nussenzweig, Michel C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaufmann, Daniel E. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-345655
DOI:	10.1038/s41591-019-0747-1
Journal or Publication Title:	Nat. Med.
Volume:	26
Number:	2
Page Range:	S. 222 - 244
Date:	2020
Publisher:	NATURE PUBLISHING GROUP
Place of Publication:	NEW YORK
ISSN:	1546-170X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIV-1; INFECTION; RESERVOIR; RESPONSES; VIREMIA Multiple languages Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34565